Rivoceranib

Generic Name
Rivoceranib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C24H23N5O
CAS Number
811803-05-1
Unique Ingredient Identifier
5S371K6132
Background

Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).

Indication

本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma

First Posted Date
2018-02-05
Last Posted Date
2018-02-05
Lead Sponsor
Peking University Cancer Hospital & Institute
Target Recruit Count
30
Registration Number
NCT03422445
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, China

Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)

Phase 2
Conditions
NSCLC
Interventions
Drug: Apatinib
Drug: Docetaxel
First Posted Date
2018-01-31
Last Posted Date
2018-01-31
Lead Sponsor
Affiliated Hospital of North Sichuan Medical College
Target Recruit Count
20
Registration Number
NCT03416231
Locations
🇨🇳

Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China

SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy

Phase 2
Completed
Conditions
Small-cell Lung Cancer
Interventions
Drug: SHR-1210
Drug: Apatinib
First Posted Date
2018-01-31
Last Posted Date
2024-08-07
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Target Recruit Count
59
Registration Number
NCT03417895
Locations
🇨🇳

Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China

🇨🇳

Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Clinical Study of Apatinib Combined With Second - Line Chemotherapy for Metastatic Colorectal Cancer

First Posted Date
2018-01-29
Last Posted Date
2018-01-29
Lead Sponsor
Liqiang Zhong
Target Recruit Count
60
Registration Number
NCT03412994

Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC

Phase 2
Conditions
Lung Cancer
Interventions
Drug: Apatinib
Drug: Docetaxel
First Posted Date
2018-01-26
Last Posted Date
2018-01-26
Lead Sponsor
Zigong No.1 Peoples Hospital
Target Recruit Count
20
Registration Number
NCT03411967

Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies

First Posted Date
2018-01-23
Last Posted Date
2020-07-15
Lead Sponsor
University of Utah
Target Recruit Count
5
Registration Number
NCT03407976
Locations
🇺🇸

Huntsman Cancer Institute, Salt Lake City, Utah, United States

Apatinib in the Treatment of Metastatic Colorectal Cancer

Phase 2
Conditions
Colorectal Cancer
Interventions
Drug: Apatinib
First Posted Date
2018-01-18
Last Posted Date
2018-01-18
Lead Sponsor
Fudan University
Target Recruit Count
33
Registration Number
NCT03403452
Locations
🇨🇳

Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma

Not Applicable
Conditions
Hepatocellular Carcinoma
Interventions
Procedure: TACE
Drug: Apatinib
First Posted Date
2018-01-12
Last Posted Date
2018-01-12
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
248
Registration Number
NCT03398122
Locations
🇨🇳

Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China

A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer

Phase 1
Completed
Conditions
Cancer
Interventions
Drug: Apatinib
Drug: Nivolumab
First Posted Date
2018-01-10
Last Posted Date
2023-04-07
Lead Sponsor
Elevar Therapeutics
Target Recruit Count
30
Registration Number
NCT03396211
Locations
🇺🇸

Sarcoma Oncology Research Center, Santa Monica, California, United States

A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC

Phase 2
Completed
Conditions
Breast Cancer
Interventions
Drug: SHR-1210
Drug: Apatinib
First Posted Date
2018-01-09
Last Posted Date
2020-10-23
Lead Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Target Recruit Count
40
Registration Number
NCT03394287
Locations
🇨🇳

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy